Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3–17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial

BACKGROUND: ZF2001 is a recombinant protein subunit vaccine against SARS-CoV-2 that has been approved for use in China, Colombia, Indonesia, and Uzbekistan in adults aged 18 years or older, but not yet in children and adolescents younger than 18 years. We aimed to evaluate the safety and immunogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lidong, Li, Yan, He, Peng, Chen, Zhen, Yang, Huaiyu, Li, Fangjun, Zhang, Siyuan, Wang, Danni, Wang, Guangyan, Yang, Shilong, Gong, Lihui, Ding, Fan, Ling, Mengyu, Wang, Xilu, Ci, Leilei, Dai, Lianpan, Gao, George Fu, Huang, Tao, Hu, Zhongyu, Ying, Zhifang, Sun, Jiufeng, Zuo, Xiaohu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937662/
https://www.ncbi.nlm.nih.gov/pubmed/36803632
http://dx.doi.org/10.1016/S2352-4642(22)00376-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937662/
https://www.ncbi.nlm.nih.gov/pubmed/36803632
http://dx.doi.org/10.1016/S2352-4642(22)00376-5

Ejemplares similares